Home・Akcijų sąrašas・Insmed

Insmed

Uždarymo kaina

SektoriusSveikatos priežiūra

98.72 0.46

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

96.22

Max

99.38

Pagrindiniai rodikliai
By Trading Economics
Pajamos	165M -164M
Pardavimai	42M 306M
Pelnas, tenkantis vienai akcijai	-0.76
Pelno marža	-53.458
Darbuotojai	1,664
EBITDA	164M -136M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+100.98% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-7.5B 23B
Ankstesnė atidarymo kaina	98.26
Ankstesnė uždarymo kaina	98.72

Naujienos nuotaikos

By Acuity

43%

57%

135 / 340 reitingas Healthcare

Insmed Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-03 19:16; UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

2026-07-31 20:06; UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

2026-07-30 21:16; UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

2026-07-28 19:26; UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

2026-07-27 23:41; UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

2026-07-24 23:46; UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

2026-07-22 19:11; UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

2026-07-21 17:41; UTC

Social Media

News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

2026-07-20 19:16; UTC

News

Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Akcijų palyginimas

Kainos pokytis

Insmed Prognozė

Kainos tikslas

By TipRanks

100.98% į viršų

12 mėnesių prognozė

Vidutinis 198.17 USD 100.98%

Aukščiausias 243 USD

Žemiausias 160 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Insmed kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

Pirkti

Laikyti

Parduoti

Remiantis 20 analitikų, pateikusių Insmed akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

135 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.